Literature DB >> 29775847

Strategies for a multi-stage neutralizing antibody-based HIV vaccine.

Raiees Andrabi1, Jinal N Bhiman2, Dennis R Burton3.   

Abstract

A critical property of a prophylactic HIV vaccine is likely to be its ability to elicit broadly neutralizing antibodies (bnAbs). BnAbs typically have multiple unusual features and are generated in a fraction of HIV-infected individuals through complex pathways. Current vaccine design approaches seek to trigger rare B cell precursors and then steer affinity maturation toward bnAbs in a multi-stage multi-component immunization approach. These vaccine design strategies have been facilitated by molecular descriptions of bnAb interactions with stabilized HIV trimers, the use of an array of sophisticated approaches for immunogen design, the development of novel animal models for immunogen evaluation and advanced technologies to interrogate antibody responses. In this review, we will discuss leading HIV bnAb vaccine immunogens, immunization strategies and future improvements.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29775847      PMCID: PMC6141341          DOI: 10.1016/j.coi.2018.04.025

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  59 in total

Review 1.  Use of broadly neutralizing antibodies for HIV-1 prevention.

Authors:  Amarendra Pegu; Ann J Hessell; John R Mascola; Nancy L Haigwood
Journal:  Immunol Rev       Date:  2017-01       Impact factor: 12.988

2.  Precursor Frequency and Affinity Determine B Cell Competitive Fitness in Germinal Centers, Tested with Germline-Targeting HIV Vaccine Immunogens.

Authors:  Robert K Abbott; Jeong Hyun Lee; Sergey Menis; Patrick Skog; Meghan Rossi; Takayuki Ota; Daniel W Kulp; Deepika Bhullar; Oleksandr Kalyuzhniy; Colin Havenar-Daughton; William R Schief; David Nemazee; Shane Crotty
Journal:  Immunity       Date:  2017-12-26       Impact factor: 31.745

3.  Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

Authors:  Rui Kong; Kai Xu; Tongqing Zhou; Priyamvada Acharya; Thomas Lemmin; Kevin Liu; Gabriel Ozorowski; Cinque Soto; Justin D Taft; Robert T Bailer; Evan M Cale; Lei Chen; Chang W Choi; Gwo-Yu Chuang; Nicole A Doria-Rose; Aliaksandr Druz; Ivelin S Georgiev; Jason Gorman; Jinghe Huang; M Gordon Joyce; Mark K Louder; Xiaochu Ma; Krisha McKee; Sijy O'Dell; Marie Pancera; Yongping Yang; Scott C Blanchard; Walther Mothes; Dennis R Burton; Wayne C Koff; Mark Connors; Andrew B Ward; Peter D Kwong; John R Mascola
Journal:  Science       Date:  2016-05-13       Impact factor: 47.728

4.  HIV-1 VACCINES. Priming a broadly neutralizing antibody response to HIV-1 using a germline-targeting immunogen.

Authors:  Joseph G Jardine; Takayuki Ota; Devin Sok; Matthias Pauthner; Daniel W Kulp; Oleksandr Kalyuzhniy; Patrick D Skog; Theresa C Thinnes; Deepika Bhullar; Bryan Briney; Sergey Menis; Meaghan Jones; Mike Kubitz; Skye Spencer; Yumiko Adachi; Dennis R Burton; William R Schief; David Nemazee
Journal:  Science       Date:  2015-06-18       Impact factor: 47.728

5.  Complex Antigens Drive Permissive Clonal Selection in Germinal Centers.

Authors:  Masayuki Kuraoka; Aaron G Schmidt; Takuya Nojima; Feng Feng; Akiko Watanabe; Daisuke Kitamura; Stephen C Harrison; Thomas B Kepler; Garnett Kelsoe
Journal:  Immunity       Date:  2016-03-03       Impact factor: 31.745

6.  Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies.

Authors:  Nicole A Doria-Rose; Chaim A Schramm; Jason Gorman; Penny L Moore; Jinal N Bhiman; Brandon J DeKosky; Michael J Ernandes; Ivelin S Georgiev; Helen J Kim; Marie Pancera; Ryan P Staupe; Han R Altae-Tran; Robert T Bailer; Ema T Crooks; Albert Cupo; Aliaksandr Druz; Nigel J Garrett; Kam H Hoi; Rui Kong; Mark K Louder; Nancy S Longo; Krisha McKee; Molati Nonyane; Sijy O'Dell; Ryan S Roark; Rebecca S Rudicell; Stephen D Schmidt; Daniel J Sheward; Cinque Soto; Constantinos Kurt Wibmer; Yongping Yang; Zhenhai Zhang; James C Mullikin; James M Binley; Rogier W Sanders; Ian A Wilson; John P Moore; Andrew B Ward; George Georgiou; Carolyn Williamson; Salim S Abdool Karim; Lynn Morris; Peter D Kwong; Lawrence Shapiro; John R Mascola
Journal:  Nature       Date:  2014-03-02       Impact factor: 49.962

7.  Germline-like predecessors of broadly neutralizing antibodies lack measurable binding to HIV-1 envelope glycoproteins: implications for evasion of immune responses and design of vaccine immunogens.

Authors:  Xiaodong Xiao; Weizao Chen; Yang Feng; Zhongyu Zhu; Ponraj Prabakaran; Yanping Wang; Mei-Yun Zhang; Nancy S Longo; Dimiter S Dimitrov
Journal:  Biochem Biophys Res Commun       Date:  2009-09-11       Impact factor: 3.575

8.  Viral variants that initiate and drive maturation of V1V2-directed HIV-1 broadly neutralizing antibodies.

Authors:  Jinal N Bhiman; Colin Anthony; Nicole A Doria-Rose; Owen Karimanzira; Chaim A Schramm; Thandeka Khoza; Dale Kitchin; Gordon Botha; Jason Gorman; Nigel J Garrett; Salim S Abdool Karim; Lawrence Shapiro; Carolyn Williamson; Peter D Kwong; John R Mascola; Lynn Morris; Penny L Moore
Journal:  Nat Med       Date:  2015-10-12       Impact factor: 53.440

9.  Sequential and Simultaneous Immunization of Rabbits with HIV-1 Envelope Glycoprotein SOSIP.664 Trimers from Clades A, B and C.

Authors:  P J Klasse; Celia C LaBranche; Thomas J Ketas; Gabriel Ozorowski; Albert Cupo; Pavel Pugach; Rajesh P Ringe; Michael Golabek; Marit J van Gils; Miklos Guttman; Kelly K Lee; Ian A Wilson; Salvatore T Butera; Andrew B Ward; David C Montefiori; Rogier W Sanders; John P Moore
Journal:  PLoS Pathog       Date:  2016-09-14       Impact factor: 6.823

10.  Tailored Immunogens Direct Affinity Maturation toward HIV Neutralizing Antibodies.

Authors:  Bryan Briney; Devin Sok; Joseph G Jardine; Daniel W Kulp; Patrick Skog; Sergey Menis; Ronald Jacak; Oleksandr Kalyuzhniy; Natalia de Val; Fabian Sesterhenn; Khoa M Le; Alejandra Ramos; Meaghan Jones; Karen L Saye-Francisco; Tanya R Blane; Skye Spencer; Erik Georgeson; Xiaozhen Hu; Gabriel Ozorowski; Yumiko Adachi; Michael Kubitz; Anita Sarkar; Ian A Wilson; Andrew B Ward; David Nemazee; Dennis R Burton; William R Schief
Journal:  Cell       Date:  2016-09-08       Impact factor: 41.582

View more
  41 in total

1.  Immunological mechanisms of inducing HIV immunity in infants.

Authors:  Genevieve G Fouda; Kristina De Paris; Ofer Levy; Arnaud Marchant; Glenda Gray; Sallie Permar; Mary Marovich; Anjali Singh
Journal:  Vaccine       Date:  2019-11-21       Impact factor: 3.641

2.  SOS and IP Modifications Predominantly Affect the Yield but Not Other Properties of SOSIP.664 HIV-1 Env Glycoprotein Trimers.

Authors:  Rajesh P Ringe; Philippe Colin; Jonathan L Torres; Anila Yasmeen; Wen-Hsin Lee; Albert Cupo; Andrew B Ward; P J Klasse; John P Moore
Journal:  J Virol       Date:  2019-12-12       Impact factor: 5.103

Review 3.  Advancing an HIV vaccine; advancing vaccinology.

Authors:  Dennis R Burton
Journal:  Nat Rev Immunol       Date:  2019-02       Impact factor: 53.106

4.  Targeted isolation of diverse human protective broadly neutralizing antibodies against SARS-like viruses.

Authors:  Wan-Ting He; Rami Musharrafieh; Ge Song; Katharina Dueker; Longping V Tse; David R Martinez; Alexandra Schäfer; Sean Callaghan; Peter Yong; Nathan Beutler; Jonathan L Torres; Reid M Volk; Panpan Zhou; Meng Yuan; Hejun Liu; Fabio Anzanello; Tazio Capozzola; Mara Parren; Elijah Garcia; Stephen A Rawlings; Davey M Smith; Ian A Wilson; Yana Safonova; Andrew B Ward; Thomas F Rogers; Ralph S Baric; Lisa E Gralinski; Dennis R Burton; Raiees Andrabi
Journal:  Nat Immunol       Date:  2022-06-02       Impact factor: 31.250

5.  Env-independent protection of intrarectal SIV challenge by vaccine induction of Gag/Vif-specific CD8+ T cells but not CD4+ T cells.

Authors:  Hiroshi Ishii; Kazutaka Terahara; Takushi Nomura; Midori Okazaki; Hiroyuki Yamamoto; Tsugumine Shu; Hiromi Sakawaki; Tomoyuki Miura; David I Watkins; Tetsuro Matano
Journal:  Mol Ther       Date:  2022-02-26       Impact factor: 12.910

6.  A generalized HIV vaccine design strategy for priming of broadly neutralizing antibody responses.

Authors:  Jon M Steichen; Ying-Cing Lin; Colin Havenar-Daughton; Simone Pecetta; Gabriel Ozorowski; Jordan R Willis; Laura Toy; Devin Sok; Alessia Liguori; Sven Kratochvil; Jonathan L Torres; Oleksandr Kalyuzhniy; Eleonora Melzi; Daniel W Kulp; Sebastian Raemisch; Xiaozhen Hu; Steffen M Bernard; Erik Georgeson; Nicole Phelps; Yumiko Adachi; Michael Kubitz; Elise Landais; Jeffrey Umotoy; Amanda Robinson; Bryan Briney; Ian A Wilson; Dennis R Burton; Andrew B Ward; Shane Crotty; Facundo D Batista; William R Schief
Journal:  Science       Date:  2019-10-31       Impact factor: 47.728

Review 7.  B Cell Responses: Cell Interaction Dynamics and Decisions.

Authors:  Jason G Cyster; Christopher D C Allen
Journal:  Cell       Date:  2019-04-18       Impact factor: 41.582

Review 8.  Vaccines and Broadly Neutralizing Antibodies for HIV-1 Prevention.

Authors:  Kathryn E Stephenson; Kshitij Wagh; Bette Korber; Dan H Barouch
Journal:  Annu Rev Immunol       Date:  2020-04-26       Impact factor: 32.481

9.  Neutralizing Antibodies Induced by First-Generation gp41-Stabilized HIV-1 Envelope Trimers and Nanoparticles.

Authors:  Sonu Kumar; Xiaohe Lin; Timothy Ngo; Benjamin Shapero; Cindy Sou; Joel D Allen; Jeffrey Copps; Lei Zhang; Gabriel Ozorowski; Linling He; Max Crispin; Andrew B Ward; Ian A Wilson; Jiang Zhu
Journal:  mBio       Date:  2021-06-22       Impact factor: 7.867

10.  HIV envelope trimer-elicited autologous neutralizing antibodies bind a region overlapping the N332 glycan supersite.

Authors:  Bartek Nogal; Laura E McCoy; Marit J van Gils; Christopher A Cottrell; James E Voss; Raiees Andrabi; Matthias Pauthner; Chi-Hui Liang; Terrence Messmer; Rebecca Nedellec; Mia Shin; Hannah L Turner; Gabriel Ozorowski; Rogier W Sanders; Dennis R Burton; Andrew B Ward
Journal:  Sci Adv       Date:  2020-06-05       Impact factor: 14.136

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.